Establishment of Mouse Models of Psoriasis with Blood Stasis Syndrome Complicated with Glucose and Lipid Metabolism Disorders.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
08
2019
accepted:
21
10
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
30
11
2019
Statut:
epublish
Résumé
Psoriasis has been reported as a high-risk factor for quality of life and survival rate in patients with metabolic disorder. However, there is no animal model for studying this disease. This study aimed to establish and evaluate mouse models of psoriasis with blood stasis syndrome (which is a key to psoriasis pathogenesis, according to Chinese Medicine) complicated with metabolic disorders. Forty-five C57BL/6 mice were randomly divided into the blank control (Control), psoriasis (Imiquimod (IMQ)), psoriasis with metabolic disorders (IMQ + streptozotocin (STZ)), psoriasis with blood stasis syndrome (BSS) (IMQ + BSS), and psoriasis with blood stasis syndrome complicated with metabolic disorders (IMQ + STZ + BSS) groups ( Laboratory indexes in the four model groups were significantly different from those in the Control group ( The established mouse models of psoriasis blood stasis syndrome complicated with glucose and lipid metabolism disorders met the clinical and Chinese Medicine characteristics, and thus they could be used as animal models in future studies of psoriasis complicated with glucose and lipid metabolism disorders.
Sections du résumé
BACKGROUND
BACKGROUND
Psoriasis has been reported as a high-risk factor for quality of life and survival rate in patients with metabolic disorder. However, there is no animal model for studying this disease. This study aimed to establish and evaluate mouse models of psoriasis with blood stasis syndrome (which is a key to psoriasis pathogenesis, according to Chinese Medicine) complicated with metabolic disorders.
METHOD
METHODS
Forty-five C57BL/6 mice were randomly divided into the blank control (Control), psoriasis (Imiquimod (IMQ)), psoriasis with metabolic disorders (IMQ + streptozotocin (STZ)), psoriasis with blood stasis syndrome (BSS) (IMQ + BSS), and psoriasis with blood stasis syndrome complicated with metabolic disorders (IMQ + STZ + BSS) groups (
RESULTS
RESULTS
Laboratory indexes in the four model groups were significantly different from those in the Control group (
CONCLUSIONS
CONCLUSIONS
The established mouse models of psoriasis blood stasis syndrome complicated with glucose and lipid metabolism disorders met the clinical and Chinese Medicine characteristics, and thus they could be used as animal models in future studies of psoriasis complicated with glucose and lipid metabolism disorders.
Identifiants
pubmed: 31781274
doi: 10.1155/2019/6419509
pmc: PMC6875367
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6419509Informations de copyright
Copyright © 2019 Ying Luo et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this article.
Références
Biochim Biophys Acta. 2014 Jan;1844(1 Pt B):280-8
pubmed: 23747921
Arch Dermatol. 2011 Apr;147(4):419-24
pubmed: 21173301
Ann Transl Med. 2019 Sep;7(18):488
pubmed: 31700924
Prim Care Diabetes. 2017 Feb;11(1):52-56
pubmed: 27460887
Chin Med. 2018 Mar 23;13:16
pubmed: 29588654
Medicine (Baltimore). 2018 Jul;97(27):e11394
pubmed: 29979432
Phytomedicine. 2019 Apr 25;62:152940
pubmed: 31100680
BMJ. 2006 Apr 15;332(7546):878-82
pubmed: 16510492
J Pharm Pharmacol. 2008 Sep;60(9):1167-73
pubmed: 18718120
J Dermatol Sci. 2008 Apr;50(1):1-14
pubmed: 17601706
Acta Derm Venereol. 2010 Mar;90(2):147-51
pubmed: 20169297
Chin J Integr Med. 2015 Jan;21(1):10-6
pubmed: 25246139
Mediators Inflamm. 2010;2010:null
pubmed: 20706605
J Invest Dermatol. 2019 Jun;139(6):1329-1338.e7
pubmed: 30776434
Methods Find Exp Clin Pharmacol. 2004 Jun;26(5):327-33
pubmed: 15319810
Medicine (Baltimore). 2019 Feb;98(8):e14543
pubmed: 30813162
PLoS One. 2015 Dec 23;10(12):e0145221
pubmed: 26700640
Rev Esp Enferm Dig. 2019 Apr;111(4):314-319
pubmed: 30939889
BMC Dermatol. 2012 Oct 30;12:20
pubmed: 23110323
J Biol Chem. 2003 Jan 3;278(1):471-8
pubmed: 12409292
Afr J Tradit Complement Altern Med. 2017 Jun 05;14(4):96-107
pubmed: 28638872
Can J Cardiol. 2015 Mar;31(3):287-95
pubmed: 25660150
Evid Based Complement Alternat Med. 2016;2016:1327251
pubmed: 27418936
J Int Med Res. 2014 Oct;42(5):1118-22
pubmed: 25143337
Medicine (Baltimore). 2016 May;95(19):e3676
pubmed: 27175702
J Immunol. 2009 May 1;182(9):5836-45
pubmed: 19380832
Br J Dermatol. 1995 Apr;132(4):497-505
pubmed: 7538318